PMCB vs RMD · $8.6M cap vs P/E 29, rev $5.65B
PharmaCyte Biotech Inc (PMCB) versus ResMed Inc (RMD) — a side-by-side from cached financials, not a winner call.
PharmaCyte Biotech Inc (PMCB) is a biotechnology company listed on NASDAQ.
ResMed Inc (RMD) is a medical instruments & supplies company listed on US.
Latest reported PMCB revenue for 2026-04-30 was $0. Net income was -$19.4M. PMCB currently screens at market cap $8.6M.
Latest reported RMD revenue for 2026-06-30 was $5.65B. Net income was $1.52B. Revenue was up 9.9% from 2025-06-30 to 2026-06-30. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
PMCB currently screens at market cap $8.6M. RMD currently screens at market cap $37.68B and trailing P/E 28.8.
Not investment advice. Open the PMCB and RMD stock pages for the full models.
Not investment advice.